Fernández-Vega Ophthalmological Institute, Surgery Department, School of Medicine, University of Oviedo, Spain.
J Cataract Refract Surg. 2010 Aug;36(8):1349-57. doi: 10.1016/j.jcrs.2010.02.022.
To assess the safety, efficacy, stability, and predictability after implantation of a toric intraocular copolymer (Collamer) lens (pIOL) to correct high myopic astigmatism.
Fernández-Vega Ophthalmological Institute, Oviedo, Spain.
This study evaluated eyes that had implantation of a toric pIOL. Outcome measures were the uncorrected (UDVA) and corrected (CDVA) distance visual acuities (Snellen decimal), refraction, and postoperative complications.
The study included 15 eyes of 12 patients (9 women). Preoperatively, the mean manifest spherical refraction was -1.98 diopters (D) +/- 1.32 (SD) (range -0.50 to -5.50 D) and the mean refractive cylinder, -4.85 +/- 0.83 D (range -6.50 to -4.00 D). At 12 months, the mean refractive cylinder was -0.55 +/- 0.52 D (range -1.50 to 0.00 D), with 93.3% of eyes having less than 1.00 D of cylinder. The mean spherical equivalent was -0.31 +/- 0.42 (range -1.00 to 0.75 D), with more than 70% of eyes within +/-0.50 D of the target. For the astigmatic components, 93.3% of eyes were within +/-1.00 D of J0 (r(2) = 0.98) and all eyes were within +/-1.00 D of J45 (r(2) = 0.98). The mean UDVA was 0.70 +/- 0.20 and the mean CDVA, 0.83 +/- 0.12. The overall efficacy index was 0.90. Postoperatively, all eyes had unchanged CDVA or gained 1 or more lines.
The refractive outcomes and improvement in UDVA and CDVA were rapidly achieved and remained fairly consistent throughout the follow-up period, supporting the use of toric pIOLs in eyes with high astigmatism.
No author has a financial or proprietary interest in any material or method mentioned.
评估植入矫正高度近视散光的 toric 型高分子(Collamer)人工晶状体(pIOL)的安全性、有效性、稳定性和可预测性。
西班牙奥维多费尔南德斯-维加眼科研究所。
本研究评估了植入 toric pIOL 的患者。评估指标包括未矫正(UDVA)和矫正(CDVA)远视力(Snellen 十进制)、屈光度和术后并发症。
该研究共纳入 12 例(9 名女性)15 只眼。术前平均角膜散光屈光度为-1.98 屈光度(D)±1.32(SD)(范围-0.50 至-5.50 D),平均等效球镜为-4.85±0.83 D(范围-6.50 至-4.00 D)。术后 12 个月,平均等效球镜为-0.55±0.52 D(范围-1.50 至 0.00 D),93.3%的眼柱镜度数小于 1.00 D。平均等效球镜为-0.31±0.42(范围-1.00 至 0.75 D),70%以上的眼在目标值的±0.50 D 范围内。对于散光成分,93.3%的眼在 J0 处的差值在±1.00 D 以内(r(2)=0.98),所有眼在 J45 处的差值在±1.00 D 以内(r(2)=0.98)。平均 UDVA 为 0.70±0.20,平均 CDVA 为 0.83±0.12。总体疗效指数为 0.90。术后所有眼的 CDVA 均未改变或增加 1 行或更多。
屈光结果以及 UDVA 和 CDVA 的改善在随访期间迅速实现,并保持相对稳定,支持在高度散光眼使用 toric pIOL。
无作者在文中提到的任何材料或方法上有财务或专有利益。